Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 93

1.

Immediate Effects of Dasatinib on the Migration and Redistribution of Naïve and Memory Lymphocytes Associated With Lymphocytosis in Chronic Myeloid Leukemia Patients.

Colom-Fernández B, Kreutzman A, Marcos-Jiménez A, García-Gutiérrez V, Cuesta-Mateos C, Portero-Sainz I, Pérez-García Y, Casado LF, Sánchez-Guijo F, Martínez-López J, Ayala RM, Boqué C, Xicoy B, Montero I, Soto C, Paz R, Silva G, Vega-Piris L, Steegmann JL, Muñoz-Calleja C.

Front Pharmacol. 2019 Nov 25;10:1340. doi: 10.3389/fphar.2019.01340. eCollection 2019.

2.

Comparison of flow-FISH and MM-qPCR telomere length assessment techniques for the screening of telomeropathies.

Ferreira MSV, Kirschner M, Halfmeyer I, Estrada N, Xicoy B, Isfort S, Vieri M, Zamora L, Abels A, Bouillon AS, Begemann M, Schemionek M, Maurer A, Koschmieder S, Wilop S, Panse J, Brümmendorf TH, Beier F.

Ann N Y Acad Sci. 2019 Oct 24. doi: 10.1111/nyas.14248. [Epub ahead of print]

PMID:
31647584
3.

Current treatment of myeloproliferative neoplasias: three scenarios.

Xicoy B, Zamora L.

Med Clin (Barc). 2020 Feb 28;154(4):131-133. doi: 10.1016/j.medcli.2019.05.009. Epub 2019 Jul 24. English, Spanish. No abstract available.

PMID:
31351663
4.

Diagnostic and prognostic contribution of targeted NGS in patients with triple-negative myeloproliferative neoplasms.

Acha P, Xandri M, Fuster-Tormo F, Palomo L, Xicoy B, Cabezón M, Marcé S, Granada I, Vela D, Sagüés M, Boque C, Plensa E, Pineda A, Feliu E, Solé F, Zamora L.

Am J Hematol. 2019 Oct;94(10):E264-E267. doi: 10.1002/ajh.25580. Epub 2019 Aug 6. No abstract available.

PMID:
31321810
5.

International sentinel site surveillance of patients with transfusional hemosiderosis treated with deferasirox in actual practice setting.

El-Beshlawy A, Inusa B, Beneitez Pastor D, Xicoy B, Soledada Duran Nieto M, Bruederle A, Azmon A, Gilotti G, Elalfy M.

Hematology. 2019 Dec;24(1):238-246. doi: 10.1080/16078454.2018.1558758.

PMID:
30558524
6.

Indications and use of, and incidence of major bleeding with, antithrombotic agents in myelodysplastic syndrome.

Sorigue M, Nieto J, Santos-Gomez M, Sarrate E, Jiménez MJ, Morales-Indiano C, Lopez-Viaplana L, Orna E, Navarro JT, Ribera JM, Xicoy B.

Leuk Res. 2018 Oct;73:24-28. doi: 10.1016/j.leukres.2018.08.017. Epub 2018 Aug 31.

PMID:
30193204
7.

The IPSS-R has prognostic impact in untreated patients with MDS del(5q).

Kaivers J, Lauseker M, Hildebrandt B, Fenaux P, Pfeilstöcker M, Valent P, Platzbecker U, Latagliata R, Oliva EN, Xicoy B, Götze K, Ganster C, Haase D, Bug G, Kündgen A, Gattermann N, Haas R, Germing U.

Leuk Res. 2018 Sep;72:27-33. doi: 10.1016/j.leukres.2018.07.019. Epub 2018 Jul 23.

PMID:
30075323
8.

Hydroxyurea-Induced Pneumopathy in a Patient With Myeloproliferative Syndrome.

Galván OP, Moltó HP, Fabià-Mayans A, Xicoy B, Mate JL, Martí PR.

Clin Med Insights Case Rep. 2018 Apr 23;11:1179547618770688. doi: 10.1177/1179547618770688. eCollection 2018.

9.

The division of chronic myelomonocytic leukemia (CMML)-1 into CMML-0 and CMML-1 according to 2016 World Health Organization (WHO) classification has no impact in outcome in a large series of patients from the Spanish group of MDS.

Xicoy B, Triguero A, Such E, García O, Jiménez MJ, Arnán M, Bernal T, Diaz-Beya M, Valcárcel D, Pedro C, Ramos F, Amigo ML, Collado R, Palomo L, Ardanaz MT, Cedena MT, Grau J, Zamora L, Sanz G.

Leuk Res. 2018 Jul;70:34-36. doi: 10.1016/j.leukres.2018.05.003. Epub 2018 May 9. No abstract available.

PMID:
29775844
10.

Impact of mutational studies on the diagnosis and the outcome of high-risk myelodysplastic syndromes and secondary acute myeloid leukemia patients treated with 5-azacytidine.

Cabezón M, Bargay J, Xicoy B, García O, Borrás J, Tormo M, Marcé S, Pedro C, Valcárcel D, Jiménez MJ, Guàrdia R, Palomo L, Brunet S, Vall-Llovera F, Garcia A, Feliu E, Zamora L; CETLAM Group.

Oncotarget. 2018 Apr 10;9(27):19342-19355. doi: 10.18632/oncotarget.25046. eCollection 2018 Apr 10.

11.

Targeted deep sequencing of CD34+ cells from peripheral blood can reproduce bone marrow molecular profile in myelodysplastic syndromes.

Martin R, Acha P, Ganster C, Palomo L, Dierks S, Fuster-Tormo F, Mallo M, Ademà V, Gómez-Marzo P, De Haro N, Solanes N, Zamora L, Xicoy B, Shirneshan K, Flach J, Braulke F, Schanz J, Kominowski A, Stromburg M, Brockmann A, Trümper L, Solé F, Haase D.

Am J Hematol. 2018 Jun;93(6):E152-E154. doi: 10.1002/ajh.25089. Epub 2018 Apr 10. No abstract available.

12.

DNA methylation profile in chronic myelomonocytic leukemia associates with distinct clinical, biological and genetic features.

Palomo L, Malinverni R, Cabezón M, Xicoy B, Arnan M, Coll R, Pomares H, García O, Fuster-Tormo F, Grau J, Feliu E, Solé F, Buschbeck M, Zamora L.

Epigenetics. 2018;13(1):8-18. doi: 10.1080/15592294.2017.1405199. Epub 2018 Feb 6.

13.

Second neoplasms in adult patients submitted to haematopoietic stem cell transplantation.

Torrent A, Ferrá C, Morgades M, Jiménez MJ, Sancho JM, Vives S, Batlle M, Moreno M, Xicoy B, Oriol A, Ibarra G, Ribera JM.

Med Clin (Barc). 2018 Jun 8;150(11):421-427. doi: 10.1016/j.medcli.2017.07.004. Epub 2017 Sep 2. English, Spanish.

PMID:
28874263
14.

Multidimensional assessment of patient condition and mutational analysis in peripheral blood, as tools to improve outcome prediction in myelodysplastic syndromes: A prospective study of the Spanish MDS group.

Ramos F, Robledo C, Pereira A, Pedro C, Benito R, de Paz R, Del Rey M, Insunza A, Tormo M, Díez-Campelo M, Xicoy B, Salido E, Sánchez-Del-Real J, Arenillas L, Florensa L, Luño E, Del Cañizo C, Sanz GF, María Hernández-Rivas J; Spanish Group for Myelodysplastic Syndromes (GESMD).

Am J Hematol. 2017 Sep;92(9):E534-E541. doi: 10.1002/ajh.24813. Epub 2017 Jul 19.

15.

Inspecting Targeted Deep Sequencing of Whole Genome Amplified DNA Versus Fresh DNA for Somatic Mutation Detection: A Genetic Study in Myelodysplastic Syndrome Patients.

Palomo L, Fuster-Tormo F, Alvira D, Ademà V, Armengol MP, Gómez-Marzo P, de Haro N, Mallo M, Xicoy B, Zamora L, Solé F.

Biopreserv Biobank. 2017 Aug;15(4):360-365. doi: 10.1089/bio.2016.0094. Epub 2017 Jun 6.

PMID:
28586236
16.

Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS-R).

Calvo X, Arenillas L, Luño E, Senent L, Arnan M, Ramos F, Pedro C, Tormo M, Montoro J, Díez-Campelo M, Blanco ML, Arrizabalaga B, Xicoy B, Bonanad S, Jerez A, Nomdedeu M, Ferrer A, Sanz GF, Florensa L.

Am J Hematol. 2017 Jul;92(7):614-621. doi: 10.1002/ajh.24732. Epub 2017 May 9.

17.

Usefulness of bronchoalveolar lavage and flow cytometry in patients with hematological malignancies and respiratory failure.

Ferrà C, Xicoy B, Castillo N, Morgades M, Juncà J, Andreo F, Millá F, Feliu E, Ribera JM.

Med Clin (Barc). 2017 Apr 7;148(7):297-302. doi: 10.1016/j.medcli.2016.10.045. Epub 2017 Jan 28. English, Spanish.

PMID:
28143650
18.

Erythroleukemia shares biological features and outcome with myelodysplastic syndromes with excess blasts: a rationale for its inclusion into future classifications of myelodysplastic syndromes.

Calvo X, Arenillas L, Luño E, Senent L, Arnan M, Ramos F, Ardanaz MT, Pedro C, Tormo M, Montoro J, Díez-Campelo M, Arrizabalaga B, Xicoy B, Bonanad S, Jerez A, Nomdedeu B, Ferrer A, Sanz GF, Florensa L.

Mod Pathol. 2016 Dec;29(12):1541-1551. doi: 10.1038/modpathol.2016.146. Epub 2016 Aug 26.

19.

Targeted deep sequencing improves outcome stratification in chronic myelomonocytic leukemia with low risk cytogenetic features.

Palomo L, Garcia O, Arnan M, Xicoy B, Fuster F, Cabezón M, Coll R, Ademà V, Grau J, Jiménez MJ, Pomares H, Marcé S, Mallo M, Millá F, Alonso E, Sureda A, Gallardo D, Feliu E, Ribera JM, Solé F, Zamora L.

Oncotarget. 2016 Aug 30;7(35):57021-57035. doi: 10.18632/oncotarget.10937.

20.

Considering Bone Marrow Blasts From Nonerythroid Cellularity Improves the Prognostic Evaluation of Myelodysplastic Syndromes.

Arenillas L, Calvo X, Luño E, Senent L, Alonso E, Ramos F, Ardanaz MT, Pedro C, Tormo M, Marco V, Montoro J, Díez-Campelo M, Brunet S, Arrizabalaga B, Xicoy B, Andreu R, Bonanad S, Jerez A, Nomdedeu B, Ferrer A, Sanz GF, Florensa L.

J Clin Oncol. 2016 Sep 20;34(27):3284-92. doi: 10.1200/JCO.2016.66.9705. Epub 2016 Jul 5.

PMID:
27382099
21.

Impact of anaemia on health-related quality of life and cardiac remodelling in patients with lower risk myelodysplastic syndromes. Results of GlobQoL study.

Ramos F, Pedro C, Tormo M, de Paz R, Font P, Luño E, Caballero M, Solano F, Almagro M, Xicoy B, Jiménez M.

Eur J Cancer Care (Engl). 2017 Nov;26(6). doi: 10.1111/ecc.12426. Epub 2016 Jan 4.

PMID:
26729645
22.

Highly variable mutational profile of ASXL1 in myelofibrosis.

Sorigué M, Ribera JM, García O, Cabezón M, Vélez P, Marcé S, Xicoy B, Fernández C, Buch J, Cortes M, Plensa E, Gallardo D, Boqué C, Feliu E, Zamora L.

Eur J Haematol. 2016 Oct;97(4):331-5. doi: 10.1111/ejh.12731. Epub 2016 Jan 19.

PMID:
26714837
23.

Use of newer prognostic indices for patients with myelodysplastic syndromes in the low and intermediate-1 risk categories: a population-based study.

Valcárcel D, Sanz G, Ortega M, Nomdedeu B, Luño E, Diez-Campelo M, Ardanaz MT, Pedro C, Montoro J, Collado R, Andreu R, Marco V, Cedena MT, de Paz R, Tormo M, Xicoy B, Ramos F, Bargay J, Gonzalez B, Brunet S, Muñoz JA, Gomez V, Bailén A, Sanchez J, Merchán B, del Cañizo C, Vallespí T; Grupo Español de Síndromes Mielodisplásicos (GESMD).

Lancet Haematol. 2015 Jun;2(6):e260-6. doi: 10.1016/S2352-3026(15)00067-8. Epub 2015 May 20.

PMID:
26688236
24.

Impact of SNP array karyotyping on the diagnosis and the outcome of chronic myelomonocytic leukemia with low risk cytogenetic features or no metaphases.

Palomo L, Xicoy B, Garcia O, Mallo M, Ademà V, Cabezón M, Arnan M, Pomares H, José Larrayoz M, José Calasanz M, Maciejewski JP, Huang D, Shih LY, Ogawa S, Cervera J, Such E, Coll R, Grau J, Solé F, Zamora L.

Am J Hematol. 2016 Feb;91(2):185-92. doi: 10.1002/ajh.24227. Epub 2015 Dec 9.

25.

Comparison of three prognostic scoring systems in a series of 146 cases of chronic myelomonocytic leukemia (CMML): MD Anderson prognostic score (MDAPS), CMML-specific prognostic scoring system (CPSS) and Mayo prognostic model. A detailed review of prognostic factors in CMML.

Calvo X, Nomdedeu M, Santacruz R, Martínez N, Costa D, Pereira A, Estrada N, Xicoy B, Esteve J, Nomdedeu B.

Leuk Res. 2015 Jul 23. pii: S0145-2126(15)30324-6. doi: 10.1016/j.leukres.2015.05.017. [Epub ahead of print]

PMID:
26354683
26.

Response to erythropoietic-stimulating agents in patients with chronic myelomonocytic leukemia.

Xicoy B, Germing U, Jimenez MJ, Garcia O, Garcia R, Schemenau J, Pedro C, Luño E, Bernal T, González B, Strupp C, Ardanaz M, Kuendgen A, Cedena MT, Neukirchen J, Calabuig M, Brunet S, Medina A, Amigo ML, Ramos F, Callejas M, Díez-Campelo M, Bailén A, Collado R, Vicente A, Arnan M, Valcarcel D, Arilla MJ, Zamora L, Benlloch L, Sanz G.

Eur J Haematol. 2016 Jul;97(1):33-8. doi: 10.1111/ejh.12679. Epub 2015 Oct 22.

PMID:
26341961
27.

Long-term results of prednisone treatment for the anemia of myelofibrosis.

Hernández-Boluda JC, Martínez-Trillos A, García-Gutiérrez V, Ferrer-Marín F, Xicoy B, Alvarez-Larrán A, Kerguelen A, Barba P, Gómez M, Herrera JC, Correa JG, Cervantes F.

Leuk Lymphoma. 2016;57(1):120-4. doi: 10.3109/10428194.2015.1046866. Epub 2015 Jun 18.

PMID:
25944376
28.

Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry.

Bernal T, Martínez-Camblor P, Sánchez-García J, de Paz R, Luño E, Nomdedeu B, Ardanaz MT, Pedro C, Amigo ML, Xicoy B, del Cañizo C, Tormo M, Bargay J, Valcárcel D, Brunet S, Benlloch L, Sanz G; Spanish Group on Myelodysplastic Syndromes; PETHEMA Foundation; Spanish Society of Hematology.

Leukemia. 2015 Sep;29(9):1875-81. doi: 10.1038/leu.2015.115. Epub 2015 May 6.

PMID:
25943181
29.

Co-existence of JAK2 V617F and CALR mutations in primary myelofibrosis.

Zamora L, Xicoy B, Cabezón M, Fernandez C, Marcé S, Velez P, Xandri M, Gallardo D, Millá F, Feliu E, Boqué C.

Leuk Lymphoma. 2015;56(10):2973-4. doi: 10.3109/10428194.2015.1015124. Epub 2015 Mar 11. No abstract available.

PMID:
25686645
30.

Rabbit antithymocyte globulin versus horse antithymocyte globulin for treatment of acquired aplastic anemia: a retrospective analysis.

Vallejo C, Montesinos P, Polo M, Cuevas B, Morado M, Rosell A, Xicoy B, Díez JL, Salamero O, Cedillo Á, Martínez P, Rayón C; Bone Marrow Failure Spanish Study Group (Pethema-GETH).

Ann Hematol. 2015 Jun;94(6):947-54. doi: 10.1007/s00277-015-2305-3. Epub 2015 Feb 13.

PMID:
25672649
31.

Criteria for evaluating response and outcome in clinical trials for children with juvenile myelomonocytic leukemia.

Niemeyer CM, Loh ML, Cseh A, Cooper T, Dvorak CC, Chan R, Xicoy B, Germing U, Kojima S, Manabe A, Dworzak M, De Moerloose B, Starý J, Smith OP, Masetti R, Catala A, Bergstraesser E, Ussowicz M, Fabri O, Baruchel A, Cavé H, Zwaan M, Locatelli F, Hasle H, van den Heuvel-Eibrink MM, Flotho C, Yoshimi A.

Haematologica. 2015 Jan;100(1):17-22. doi: 10.3324/haematol.2014.109892.

32.

Multivariable time-dependent analysis of the impact of azacitidine in patients with lower-risk myelodysplastic syndrome and unfavorable specific lower-risk score.

Falantes J, Delgado RG, Calderón-Cabrera C, Márquez-Malaver FJ, Valcarcel D, de Miguel D, Bailén A, Bargay J, Bernal T, González-Porras JR, Tormo M, Ramos F, Andreu R, Xicoy B, Nomdedeu B, Brunet S, Sánchez J, Jurado AF, Bonanad S, Pérez-Simón JA, Sanz G; Spanish Group of Myelodysplastic Syndromes (GESMD).

Leuk Res. 2015 Jan;39(1):52-7. doi: 10.1016/j.leukres.2014.10.004. Epub 2014 Oct 30.

PMID:
25487012
33.

Refined medullary blast and white blood cell count based classification of chronic myelomonocytic leukemias.

Schuler E, Schroeder M, Neukirchen J, Strupp C, Xicoy B, Kündgen A, Hildebrandt B, Haas R, Gattermann N, Germing U.

Leuk Res. 2014 Dec;38(12):1413-9. doi: 10.1016/j.leukres.2014.09.003. Epub 2014 Sep 17.

PMID:
25444076
34.

Calreticulin mutations are not present in patients with myeloproliferative chronic myelomonocytic leukemia.

Zamora L, Germing U, Cabezón M, Schuler E, Arnan M, Marcé S, Coll R, Pomares H, Brings C, Palomo L, Schmeneau J, Gallardo D, Millá F, Feliu E, Xicoy B.

Ann Hematol. 2015 May;94(5):869-71. doi: 10.1007/s00277-014-2262-2. Epub 2014 Nov 22. No abstract available.

PMID:
25413337
35.

Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: a multi-institutional retrospective study.

Castillo JJ, Bower M, Brühlmann J, Novak U, Furrer H, Tanaka PY, Besson C, Montoto S, Cwynarski K, Abramson JS, Dalia S, Bibas M, Connors JM, Furman M, Nguyen ML, Cooley TP, Beltran BE, Collins JA, Vose JM, Xicoy B, Ribera JM; HIV-Associated Hodgkin Lymphoma in the cART Era Study Group.

Cancer. 2015 Feb 1;121(3):423-31. doi: 10.1002/cncr.29066. Epub 2014 Sep 23.

36.

Results of allogeneic stem cell transplantation in the Spanish MDS registry: prognostic factors for low risk patients.

Díez Campelo M, Sánchez-Barba M, de Soria VG, Martino R, Sanz G, Insunza A, Bernal T, Duarte R, Amigo ML, Xicoy B, Tormo M, Iniesta F, Bailén A, Benlloch L, Córdoba I, López-Villar O, Del Cañizo MC; Spanish Registry of MDS.

Leuk Res. 2014 Oct;38(10):1199-206. doi: 10.1016/j.leukres.2014.07.009. Epub 2014 Aug 1.

PMID:
25139847
37.

Outcome and management of pregnancies in severe chronic neutropenia patients by the European Branch of the Severe Chronic Neutropenia International Registry.

Zeidler C, Grote UA, Nickel A, Brand B, Carlsson G, Cortesão E, Dufour C, Duhem C, Notheis G, Papadaki HA, Tamary H, Tjønnfjord GE, Tucci F, Van Droogenbroeck J, Vermylen C, Voglova J, Xicoy B, Welte K.

Haematologica. 2014 Aug;99(8):1395-402. doi: 10.3324/haematol.2013.099101. Epub 2014 Jul 4.

38.

Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea.

Alvarez-Larrán A, Martínez-Avilés L, Hernández-Boluda JC, Ferrer-Marín F, Antelo ML, Burgaleta C, Mata MI, Xicoy B, Martínez-Trillos A, Gómez-Casares MT, Durán MA, Marcote B, Ancochea A, Senín A, Angona A, Gómez M, Vicente V, Cervantes F, Bellosillo B, Besses C.

Ann Hematol. 2014 Dec;93(12):2037-43. doi: 10.1007/s00277-014-2152-7. Epub 2014 Jul 2.

PMID:
24981691
39.

[Autoimmune hemolytic anemia refractory to medical treatment after chlorine dioxide intake in a patient with idiopathic thrombocytopenic purpura].

Sorigué M, Xicoy B, Grifols JR, Ribera JM.

Med Clin (Barc). 2015 Apr 8;144(7):332-3. doi: 10.1016/j.medcli.2014.05.002. Epub 2014 Jun 18. Spanish. No abstract available.

PMID:
24952664
40.

Usefulness and safety of oral cryotherapy in the prevention of oral mucositis after conditioning regimens with high-dose melphalan for autologous stem cell transplantation for lymphoma and myeloma.

Batlle M, Morgades M, Vives S, Ferrà C, Oriol A, Sancho JM, Xicoy B, Moreno M, Magallón L, Ribera JM.

Eur J Haematol. 2014 Dec;93(6):487-91. doi: 10.1111/ejh.12386. Epub 2014 Jun 21.

PMID:
24889275
41.

Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion.

Sánchez-García J, Del Cañizo C, Lorenzo I, Nomdedeu B, Luño E, de Paz R, Xicoy B, Valcárcel D, Brunet S, Marco-Betes V, García-Pintos M, Osorio S, Tormo M, Bailén A, Cerveró C, Ramos F, Diez-Campelo M, Such E, Arrizabalaga B, Azaceta G, Bargay J, Arilla MJ, Falantes J, Serrano-López J, Sanz GF; Spanish Group on Myelodysplastic Syndromes (GES MD).

Br J Haematol. 2014 Jul;166(2):189-201. doi: 10.1111/bjh.12876. Epub 2014 Apr 10.

PMID:
24716538
42.

The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis.

Hernández-Boluda JC, Pereira A, Gómez M, Boqué C, Ferrer-Marín F, Raya JM, García-Gutiérrez V, Kerguelen A, Xicoy B, Barba P, Martínez J, Luño E, Alvarez-Larrán A, Martínez-López J, Arbelo E, Besses C; Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas.

Haematologica. 2014 Apr;99(4):e55-7. doi: 10.3324/haematol.2013.101733. Epub 2014 Jan 31. No abstract available.

43.

Dose-intensive chemotherapy including rituximab is highly effective but toxic in human immunodeficiency virus-infected patients with Burkitt lymphoma/leukemia: parallel study of 81 patients.

Xicoy B, Ribera JM, Müller M, García O, Hoffmann C, Oriol A, Hentrich M, Grande C, Wasmuth JC, Esteve J, van Lunzen J, Del Potro E, Knechten H, Brunet S, Mayr C, Escoda L, Schommers P, Alonso N, Vall-Llovera F, Pérez M, Morgades M, González J, Fernández A, Thoden J, Gökbuget N, Hoelzer D, Fätkenheuer G, Wyen C; PETHEMA Group and German HIV Lymphoma Cohort.

Leuk Lymphoma. 2014 Oct;55(10):2341-8. doi: 10.3109/10428194.2013.878933. Epub 2014 Feb 25.

PMID:
24397614
44.

Transfusion dependence development and disease evolution in patients with MDS and del(5q) and without transfusion needs at diagnosis.

Rojas SM, Díez-Campelo M, Luño E, Cabrero M, Pedro C, Calabuig M, Nomdedeu B, Cedena T, Arrizabalaga B, García M, Cerveró C, Collado R, Azaceta G, Ardanaz MT, Muñoz JA, Xicoy B, Rodríguez MJ, Bargay J, Morell MJ, Simiele A, del Cañizo C.

Leuk Res. 2014 Mar;38(3):304-9. doi: 10.1016/j.leukres.2013.11.005. Epub 2013 Nov 15.

PMID:
24333115
45.

Results of treatment with azacitidine in patients aged ≥ 75 years included in the Spanish Registry of Myelodysplastic Syndromes.

Xicoy B, Jiménez MJ, García O, Bargay J, Martínez-Robles V, Brunet S, Arilla MJ, Pérez de Oteyza J, Andreu R, Casaño FJ, Cervero CJ, Bailén A, Díez M, González B, Vicente AI, Pedro C, Bernal T, Luño E, Cedena MT, Palomera L, Simiele A, Calvo JM, Marco V, Gómez E, Gómez M, Gallardo D, Muñoz J, de Paz R, Grau J, Ribera JM, Benlloch LE, Sanz G.

Leuk Lymphoma. 2014 Jun;55(6):1300-3. doi: 10.3109/10428194.2013.834532. Epub 2013 Sep 16.

PMID:
23952246
46.

Long-term follow up of patients with human immunodeficiency virus infection and advanced stage Hodgkin's lymphoma treated with doxorubicin, bleomycin, vinblastine and dacarbazine.

Xicoy B, Miralles P, Morgades M, Rubio R, Valencia ME, Ribera JM.

Haematologica. 2013 Aug;98(8):e85-6. doi: 10.3324/haematol.2012.079921. Epub 2013 May 28. No abstract available.

47.

Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors.

Marcé S, Zamora L, Cabezón M, Xicoy B, Boqué C, Fernández C, Grau J, Navarro JT, Fernández de Sevilla A, Ribera JM, Feliu E, Millá F; Grupo ICO de estudio de mutaciones de ABL en pacientes afectos de LMC.

Med Clin (Barc). 2013 Aug 4;141(3):95-9. doi: 10.1016/j.medcli.2012.10.028. Epub 2013 Feb 22.

PMID:
23433665
48.

Pro-B acute lymphoblastic leukemia in a patient with severe congenital neutropenia: an unusual form of malignant evolution.

Juncà J, Millá F, Xicoy B, García-Caro M, Rodríguez-Hernández I, Aróstegui JI.

Leuk Lymphoma. 2013 Oct;54(10):2325-7. doi: 10.3109/10428194.2013.773999. Epub 2013 Mar 8. No abstract available.

PMID:
23391142
49.

Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia.

Such E, Germing U, Malcovati L, Cervera J, Kuendgen A, Della Porta MG, Nomdedeu B, Arenillas L, Luño E, Xicoy B, Amigo ML, Valcarcel D, Nachtkamp K, Ambaglio I, Hildebrandt B, Lorenzo I, Cazzola M, Sanz G.

Blood. 2013 Apr 11;121(15):3005-15. doi: 10.1182/blood-2012-08-452938. Epub 2013 Jan 31.

PMID:
23372164
50.

Chronic myelomonocytic leukemia diagnosed by means of mutational analysis in a patient with persistent monocytosis and tuberculosis.

Palomo L, Zamora L, Xicoy B, Cortés M, Cabezón M, Torrent A, Feliu E, Millá F, Ribera JM.

Leuk Lymphoma. 2013 Oct;54(10):2297-8. doi: 10.3109/10428194.2013.767458. Epub 2013 Feb 19. No abstract available.

PMID:
23327289

Supplemental Content

Support Center